Anand Padmanabhan MD, PhD
Chief Science Officer
Dr. Anand Padmanabhan, MD PhD is a Laboratory Medicine and Transfusion Medicine/Apheresis-trained physician. He received his medical degree from Thanjavur Medical College (India), PhD in Biochemistry from Brown University, and trained in leading programs in Laboratory Medicine (College of Physicians and Surgeons of Columbia University) and Transfusion Medicine/Apheresis (University of Pittsburgh Medical Center). He served on the faculty of the Blood Research Institute of the BloodCenter of Wisconsin for 9+ years and is currently a physician-scientist at the Mayo Clinic in Rochester, MN. He is funded by the NIH to study Heparin induced Thrombocytopenia and thrombosis (HIT), a major cause of morbidity (30% thrombosis rate) and mortality (10%) in heparin-treated patients. Dr. Padmanabhan's interests include HIT epidemiology, pathogenesis, diagnosis and treatment and he has published in these areas in leading journals such as Blood, Chest and Lancet Haematology.
PhD, MBA, JD
CEO & General Counsel
Dr. Sem is also Dean and Professor of Business, Professor of Pharmaceutical Sciences and Director of Technology Transfer at Concordia University Wisconsin. He also serves on the editorial board of PLoS One Life Sciences, the Boards of Directors for the BBB and for Ozaukee County Economic Development Corp. Dr. Sem has over 20 years of experience in drug discovery and development, and has over 60 papers and 10 issued patents. He co-founded two drug discovery and development companies (Triad and AviMed) and one social venture (Bridge to Cures) before Retham. He served as VP for Biophysics at Triad Therapeutics, where he developed a platform technology for designing focused combinatorial libraries targeting kinases and dehydrogenases. He co-founded Triad Therapeutics based on technology he developed and patented, and he assisted in securing two rounds of venture financing, totaling over $40 million. Triad was voted one of the top 10 biotech startups in the U.S. in 2001 by Drug Discovery Today, and licensed kinase drug leads to Novartis for up to $60 million. Dr. Sem received his B.S. in Chemistry from UW-Milwaukee, his Ph.D. from UW-Madison in Biochemistry and his MBA and JD degrees from Marquette University.
VP, Research & Innovation
Curtis received his Bachelor's of Science in Chemistry from the University of Wisconsin-Milwaukee. He had key collaborations with Dr. Padmanabhan on key studies on HIT pathophysiology from 2012-2019, while at the BloodCenter of Wisconsin. Curtis has authored numerous papers in high impact journals on HIT diagnosis, treatment and pathogenesis. He is intimately familiar with the technical and scientific aspects of HITDx development.
Medical Director at Adaptive Biotechnologies, Co-inventor of the HIT ELISA technology that was sold by Genetic Testing Institute (sold to Genprobe for $53M) Extensive experience in US IVD industry in Scientific and Regulatory roles. Currently active consultant in both areas.
Senior Investigator at Bloodcenter of Wisconsin, A world renowned physician researcher in platelet immunology with >100 publications. NIH funded since 1971.One of the first to identify the target of HIT antibodies (PF4 protein) and is co inventor of two patents that mark major technological advances in HIT diagnosis.
CEO at Stem Pharm Inc, >25 years’ experience in the development and commercialization of medical devices, including regulatory compliance and the 510(k) process. He is also Chair of the Healthcare Committee for the Golden Angel Investors
Principal of Alembic Biotech Consultants, Specializes in services to biotechnology companies and venture capital firms. Over 37 yrs experience in the
pharmaceutical/ biotech industry including immunoassay experience in two diagnostic companies.